SOD1 and amyotrophic lateral sclerosis: The authors reported that in adults with ALS due to SOD1 mutations, cerebral spine fluid (CSF) SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.